Researchers at Washington University School of Medicine in St. Louis found that gene therapy in mice helped build strength and significant muscle mass quickly, while reducing the severity of osteoarthritis. The gene therapy also prevented obesity, even when the mice were fed a high-fat diet.
Exercise and physical therapy often are recommended to help people who have arthritis. Both can strengthen muscle — a benefit that also can reduce joint pain. But building muscle mass and strength can take many months and be difficult in the face of joint pain from osteoarthritis, particularly for older people who are overweight.
A new study in mice at Washington University School of Medicine in St. Louis, however, suggests gene therapy one day may help those patients.
The research shows that gene therapy helped build significant muscle mass quickly and reduced the severity of osteoarthritis in the mice, even though they didn’t exercise more. The therapy also staved off obesity, even when the mice ate an extremely high-fat diet.
The study is published online May 8 in the journal Science Advances.
“Obesity is the most common risk factor for osteoarthritis,” said senior investigator Farshid Guilak, PhD, the Mildred B. Simon Research Professor of Orthopaedic Surgery and director of research at Shriners Hospitals for Children — St. Louis. “Being overweight can hinder a person’s ability to exercise and benefit fully from physical therapy. We’ve identified here a way to use gene therapy to build muscle quickly. It had a profound effect in the mice and kept their weight in check, suggesting a similar approach may be effective against arthritis, particularly in cases of morbid obesity.”
With the paper’s first author, Ruhang Tang, PhD, a senior scientist in Guilak’s laboratory, Guilak and his research team gave 8-week-old mice a single injection each of a virus carrying a gene called follistatin. The gene works to block the activity of a protein in muscle that keeps muscle growth in check. This enabled the mice to gain significant muscle mass without exercising more than usual.
Even without additional exercise, and while continuing to eat a high-fat diet, the muscle mass of these “super mice” more than doubled, and their strength nearly doubled, too. The mice also had less cartilage damage related to osteoarthritis, lower numbers of inflammatory cells and proteins in their joints, fewer metabolic problems, and healthier hearts and blood vessels than littermates that did not receive the gene therapy. The mice also were significantly less sensitive to pain.
One worry was that some of the muscle growth prompted by the gene therapy might turn out to be harmful. The heart, for example, is a muscle, and a condition called cardiac hypertrophy, in which the heart’s walls thicken, is not a good thing. But in these mice, heart function actually improved, as did cardiovascular health in general.
Longer-term studies will be needed to determine the safety of this type of gene therapy. But, if safe, the strategy could be particularly beneficial for patients with conditions such as muscular dystrophy that make it difficult to build new muscle.
In the meantime, Guilak, who also co-directs the Washington University Center for Regenerative Medicine and is a professor of biomedical engineering and of developmental biology, said more traditional methods of muscle strengthening, such as lifting weights or physical therapy, remain the first line of treatment for patients with osteoarthritis.
“Something like this could take years to develop, but we’re excited about its prospects for reducing joint damage related to osteoarthritis, as well as possibly being useful in extreme cases of obesity,” he said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Selecta Biosciences Continues To Attract Partners As Sarepta Therapeutics Signs On For Gene Therapyon June 23, 2020 at 12:19 pm
Partnership strategy for ImmTOR platform continues to pay off with Sarepta deal immediately following $100 million upfront Sobi deal. Sarepta is a big time play ...
- Philadelphia gene therapy developer, backed by $250M, makes first acquisitionon June 23, 2020 at 11:56 am
Century Therapeutics said Tuesday it has acquired a fellow cell therapy company, the year-old Philadelphia firm's first such deal.
- Sarepta Inks Agreement With Codiak to Develop Gene Therapieson June 23, 2020 at 8:14 am
Sarepta Therapeutics, Inc. SRPT and privately-held Codiak BioSciences announced that the companies have entered into a global research and option agreement to develop potent genet ...
- Sana Biotechnology raises more than $700M for cell, gene therapy effortson June 23, 2020 at 7:26 am
The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - one of the earliest commercial developers of CAR-T cell therapy technology - in 2013.
- AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing Systemon June 23, 2020 at 6:48 am
Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Jude Samulski, PhD, President, Chief Scientific Officer ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Gene therapy for osteoarthritis and obesity
- Hormone Used to Fight Obesity, Loses Fight against Sepsison June 23, 2020 at 5:01 am
The researchers then studied mice that did not have the GDF15 gene. Their results revealed that they survived ... and groups are considering using GDF15 as a complementary therapy for obesity, it’s ...
- Hormone involved in obesity could increase the risk for sepsis infectionon June 22, 2020 at 11:13 am
A group of scientists from Instituto Gulbenkian de Ciência, led by Luís Moita, discovered that a hormone that has been pointed out as a treatment for obesity reduces the resistance to infection caused ...
- Hormone involved in obesity is a risk factor for sepsison June 22, 2020 at 9:31 am
A group of scientists from Instituto Gulbenkian de Ciência (IGC), led by Luís Moita, discovered that a hormone that has been pointed out as a treatment for obesity reduces the resistance to infection ...
- CyMedica Orthopedics Completes e-vive Parent Clinical Trial for Management of Knee Osteoarthritis Painon June 16, 2020 at 5:35 am
CyMedica Orthopedics®, the leading combined muscle strengthening therapy and digital health innovator, announced today that it completed early enrollment of 159 patients in the FDA-regulated clinical ...
- Gene Therapy Market 2020 Analysis Research and Development Forecast by 2026on June 12, 2020 at 8:44 am
A recent report provides crucial insights along with application based and forecast information in the Global Gene Therapy Market. The report provides a comprehensive analysis of key factors that are ...